Pipeline - Allinky Biopharma

ALLINKY
Biopharma
ALLINKY Biopharma
Go to content


Shaping the future of Medicine



Drugs under development

Allinky’s pipeline includes two new chemical entities (NCEs):
• A MAP Kinase allosteric inhibitor for the treatment of NASH and other inflammatory diseases.
• An allosteric Ras inhibitor for the treatment of advanced pancreatic, lung, blood and colorectal cancer.
Back to content